Veracyte Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Veracyte (VCYT) Tops Q2 EPS by 9c, Revenues Beat; Boosts FY18 Revenue Guidance
July 23, 2018 4:11 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $20.56 million.
We delivered another exceptional quarter of revenue and genomic test volume growth, said Bonnie Anderson, chairman and chief executive officer of Veracyte. We saw strong growth in our Afirma business where our deep... More
